These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 35930561)

  • 1. A Mobile App Leveraging Citizenship Engagement to Perform Anonymized Longitudinal Studies in the Context of COVID-19 Adverse Drug Reaction Monitoring: Development and Usability Study.
    Di Filippo M; Avellone A; Belingheri M; Paladino ME; Riva MA; Zambon A; Pescini D
    JMIR Hum Factors; 2022 Nov; 9(4):e38701. PubMed ID: 35930561
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An evaluation of the feasibility and usability of a proof of concept mobile app for adverse event reporting post influenza vaccination.
    Wilson K; Atkinson KM; Westeinde J; Bell C; Marty K; Fergusson D; Deeks SL; Crowcroft N; Bettinger JA
    Hum Vaccin Immunother; 2016 Jul; 12(7):1738-48. PubMed ID: 26905396
    [TBL] [Abstract][Full Text] [Related]  

  • 3. "ADR PvPI" Android mobile app: Report adverse drug reaction at any time anywhere in India.
    Prakash J; Joshi K; Malik D; Mishra O; Sachan A; Kumar B; Bhushan S; Kalaiselvan V; Singh GN
    Indian J Pharmacol; 2019; 51(4):236-242. PubMed ID: 31571709
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Facilitators and Barriers to Uptake of the Med Safety Mobile App for Adverse Drug Reaction Reporting by Health Workers in Uganda: A Qualitative Study.
    Kiguba R; Zakumumpa H; Ndagije HB; Mwebaza N; Ssenyonga R; Tregunno P; Harrison K; Pirmohamed M
    Drug Saf; 2023 Jun; 46(6):565-574. PubMed ID: 37097426
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Smartphone-based mobile applications for adverse drug reactions reporting: global status and country experience.
    Fukushima A; Iessa N; Balakrishnan MR; Pal SN
    BMC Med Inform Decis Mak; 2022 May; 22(1):118. PubMed ID: 35501745
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparing the Use of a Mobile App and a Web-Based Notification Platform for Surveillance of Adverse Events Following Influenza Immunization: Randomized Controlled Trial.
    Bota AB; Bettinger JA; Sarfo-Mensah S; Lopez J; Smith DP; Atkinson KM; Bell C; Marty K; Serhan M; Zhu DT; McCarthy AE; Wilson K
    JMIR Public Health Surveill; 2023 May; 9():e39700. PubMed ID: 37155240
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Risk factors and disease profile of post-vaccination SARS-CoV-2 infection in UK users of the COVID Symptom Study app: a prospective, community-based, nested, case-control study.
    Antonelli M; Penfold RS; Merino J; Sudre CH; Molteni E; Berry S; Canas LS; Graham MS; Klaser K; Modat M; Murray B; Kerfoot E; Chen L; Deng J; Österdahl MF; Cheetham NJ; Drew DA; Nguyen LH; Pujol JC; Hu C; Selvachandran S; Polidori L; May A; Wolf J; Chan AT; Hammers A; Duncan EL; Spector TD; Ourselin S; Steves CJ
    Lancet Infect Dis; 2022 Jan; 22(1):43-55. PubMed ID: 34480857
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Micro-planning in a wide age range measles rubella (MR) campaign using mobile phone app, a case of Kenya, 2016.
    Ismail A; Tabu C; Onuekwusi I; Otieno SK; Ademba P; Kamau P; Koki B; Ngatia A; Wainaina A; Davis R
    Pan Afr Med J; 2017; 27(Suppl 3):16. PubMed ID: 29296151
    [TBL] [Abstract][Full Text] [Related]  

  • 9. What is the Safety of COVID-19 Vaccines in Immunocompromised Patients? Results from the European "Covid Vaccine Monitor" Active Surveillance Study.
    Bellitto C; Luxi N; Ciccimarra F; L'Abbate L; Raethke M; van Hunsel F; Lieber T; Mulder E; Riefolo F; Villalobos F; Thurin NH; Marques FB; Morton K; O'Shaughnessy F; Sonderlichová S; Farcas A; Janneke GE; Sturkenboom MC; Trifirò G
    Drug Saf; 2024 Jun; ():. PubMed ID: 38907947
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mobile App Design, Development, and Publication for Adverse Drug Reaction Assessments of Causality, Severity, and Preventability.
    Ithnin M; Mohd Rani MD; Abd Latif Z; Kani P; Syaiful A; Nor Aripin KN; Tengku Mohd TAM
    JMIR Mhealth Uhealth; 2017 May; 5(5):e78. PubMed ID: 28559222
    [TBL] [Abstract][Full Text] [Related]  

  • 11. First French experience of ADR reporting by patients after a mass immunization campaign with Influenza A (H1N1) pandemic vaccines: a comparison of reports submitted by patients and healthcare professionals.
    Durrieu G; Palmaro A; Pourcel L; Caillet C; Faucher A; Jacquet A; Ouaret S; Perault-Pochat MC; Kreft-Jais C; Castot A; Lapeyre-Mestre M; Montastruc JL;
    Drug Saf; 2012 Oct; 35(10):845-54. PubMed ID: 22967189
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of patient reporting of adverse drug reactions to the UK 'Yellow Card Scheme': literature review, descriptive and qualitative analyses, and questionnaire surveys.
    Avery AJ; Anderson C; Bond CM; Fortnum H; Gifford A; Hannaford PC; Hazell L; Krska J; Lee AJ; McLernon DJ; Murphy E; Shakir S; Watson MC
    Health Technol Assess; 2011 May; 15(20):1-234, iii-iv. PubMed ID: 21545758
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Increasing Patient Engagement in Pharmacovigilance Through Online Community Outreach and Mobile Reporting Applications: An Analysis of Adverse Event Reporting for the Essure Device in the US.
    Bahk CY; Goshgarian M; Donahue K; Freifeld CC; Menone CM; Pierce CE; Rodriguez H; Brownstein JS; Furberg R; Dasgupta N
    Pharmaceut Med; 2015; 29(6):331-340. PubMed ID: 26635479
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Optimizing the Acceptability, Adherence, and Inclusiveness of the COVID Radar Surveillance App: Qualitative Study Using Focus Groups, Thematic Content Analysis, and Usability Testing.
    Splinter B; Saadah NH; Chavannes NH; Kiefte-de Jong JC; Aardoom JJ
    JMIR Form Res; 2022 Sep; 6(9):e36003. PubMed ID: 35781492
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mobile-Based and Cloud-Based System for Self-management of People With Type 2 Diabetes: Development and Usability Evaluation.
    Salari R; R Niakan Kalhori S; GhaziSaeedi M; Jeddi M; Nazari M; Fatehi F
    J Med Internet Res; 2021 Jun; 23(6):e18167. PubMed ID: 34076579
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mobile Health Apps on COVID-19 Launched in the Early Days of the Pandemic: Content Analysis and Review.
    Ming LC; Untong N; Aliudin NA; Osili N; Kifli N; Tan CS; Goh KW; Ng PW; Al-Worafi YM; Lee KS; Goh HP
    JMIR Mhealth Uhealth; 2020 Sep; 8(9):e19796. PubMed ID: 32609622
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dedicated mobile application for drug adverse reaction reporting by patients with relapsing remitting multiple sclerosis (Vigip-SEP study): study protocol for a randomized controlled trial.
    Defer G; Le Caignec F; Fedrizzi S; Montastruc F; Chevanne D; Parienti JJ; Peyro-Saint-Paul L
    Trials; 2018 Mar; 19(1):174. PubMed ID: 29523169
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mobile Apps for Medication Management: Review and Analysis.
    Tabi K; Randhawa AS; Choi F; Mithani Z; Albers F; Schnieder M; Nikoo M; Vigo D; Jang K; Demlova R; Krausz M
    JMIR Mhealth Uhealth; 2019 Sep; 7(9):e13608. PubMed ID: 31512580
    [TBL] [Abstract][Full Text] [Related]  

  • 19. App Use and Usability of a Barcode-Based Digital Platform to Augment COVID-19 Contact Tracing: Postpilot Survey and Paradata Analysis.
    Scherr TF; DeSousa JM; Moore CP; Hardcastle A; Wright DW
    JMIR Public Health Surveill; 2021 Mar; 7(3):e25859. PubMed ID: 33630745
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Postmarketing Safety Monitoring After Influenza Vaccination Using a Mobile Health App: Prospective Longitudinal Feasibility Study.
    Nguyen MTH; Krause G; Keller-Stanislawski B; Glöckner S; Mentzer D; Ott JJ
    JMIR Mhealth Uhealth; 2021 May; 9(5):e26289. PubMed ID: 33960950
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.